# An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

> **NCT03987802** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 42 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Faster-acting insulin aspart

## Key facts

- **NCT ID:** NCT03987802
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2022-06-28
- **Final completion:** 2022-06-28
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987802, "An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03987802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*